Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye implant for rare vision loss gets Long-Term safety review

NCT ID NCT06971939

Recruiting now Disease control Sponsor: Neurotech Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study looks at the long-term safety of an eye implant (NT-501) for people with MacTel type 2, a rare disease that damages the center of the retina. About 285 adults who already received the implant in earlier studies will be followed, and some who had a sham procedure can now get the real implant. The main goal is to track side effects and vision changes over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MACULAR TELANGIECTASIA TYPE 2 (MACTEL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular telangiectasia type 2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MACULAR TELANGIECTASIA TYPE 2 (MACTEL)

Contacts and locations

Locations

  • Bascom Palmer

    NOT_YET_RECRUITING

    Miami, Florida, 33136, United States

  • Bay Area Retina Associates

    RECRUITING

    Walnut Creek, California, 94598, United States

  • Cerulea

    RECRUITING

    East Melbourne, Australia

  • Cincinnati Eye Institute

    RECRUITING

    Cincinnati, Ohio, 45242, United States

  • Colorado Retina

    NOT_YET_RECRUITING

    Lakewood, Colorado, 80228, United States

  • Cumberland Valley Retina Consultants

    NOT_YET_RECRUITING

    Frederick, Maryland, 21702, United States

  • Emory Eye Center

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Envision Ocular, LLC

    NOT_YET_RECRUITING

    Bloomfield, New Jersey, 07003, United States

  • Foundation for Vision Research

    RECRUITING

    Grand Rapids, Michigan, 49525, United States

  • Jules Stein Eye Institute/UCLA

    NOT_YET_RECRUITING

    Los Angeles, California, 90085, United States

  • Lion's Eye Institute

    RECRUITING

    Perth, Australia

  • Massachusetts Eye and Ear Infirmary, Retina Service

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • National Eye Institute

    NOT_YET_RECRUITING

    Bethesda, Maryland, 20892, United States

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Retina Associates of Cleveland, Inc.

    RECRUITING

    Cleveland, Ohio, 44126, United States

  • Retina Center of Texas

    RECRUITING

    Dallas, Texas, 75251, United States

  • Retina Consultants of Minnesota

    NOT_YET_RECRUITING

    Minneapolis, Minnesota, 55435, United States

  • Retina Consultants of Texas

    RECRUITING

    Houston, Texas, 77030, United States

  • Retina Northwest, P.C.

    NOT_YET_RECRUITING

    Portland, Oregon, 97221, United States

  • Scheie Eye Institute

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Scripps Health

    NOT_YET_RECRUITING

    La Jolla, California, 92037, United States

  • Southeastern Retina Associates, P.C.

    RECRUITING

    Knoxville, Tennessee, 37922, United States

  • Stanford University School of Medicine

    NOT_YET_RECRUITING

    Palo Alto, California, 94303, United States

  • Sydney Eye Hospital

    RECRUITING

    Sydney, Australia

  • Texas Retina Associates

    RECRUITING

    Dallas, Texas, 75231, United States

  • University of Utah John A. Moran Center

    NOT_YET_RECRUITING

    Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.